SENSEX, NIFTY50 rangebound; Orient Electric, RIL, Siemens Energy, Nuvoco Vistas among buzzing stocks

The Indian equity benchmarks were trading in a narrow range in noon deals on Tuesday, November 25, ahead of monthly expiry of stock and NIFTY50 November futures and option contracts.

The SENSEX traded in a band of 345 points and NIFTY50 index touched an intraday high of 26,025 and a low of 25,924 as gains in State Bank of India, Reliance Industries, Larsen & Toubro, Axis Bank and Maruti Suzuki were offset with losses in Infosys, Kotak Mahindra Bank, HCL Technologies, Tata Consultancy Services and HDFC Bank.

As of 12:08 pm, the SENSEX was up 62 points at 84,963 and NIFTY50 index advanced 24 points to 25,983.

Trading volume on the National Stock Exchange spiked by 48 times to 77.08 lakh shares compared with an average trading volume of 1.61 lakh shares.

On the BSE, 3.41 lakh shares changed hands compared with an average of 6,483 shares traded daily in the past two weeks.

According to news reports, JP Morgan is positive on the company. Analysts at the global investment firm note that the stock's valuations are attractive. They also highlighted the next catalysts for the company's growth, which are the Jio IPO, tariff hike, new energy, and retail stability.

Siemens Energy, which was demerged from Siemens Limited and listed in June this year, reported net profit of ₹360 crore in fourth quarter of financial year 2025, marking an increase of 32% from ₹273 crore in the same period last year.

Its revenue from operations jumped 27% to ₹2,646 crore during September quarter as against ₹2,079 crore in the year-ago period.

Siemens Energy reported stable operational performance as its EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) also known as operating profit advanced 25% to ₹480 crore but its EBITDA margin contracted by 40 basis points to 18.13%.

The ETF sold the company's 12,63,276 equity shares, or 0.59% stake, at an average price of ₹164.45 on the NSE.

The iShares Core MSCI Emerging Markets ETF (IEMG) is an exchange-traded fund managed by BlackRock that aims to track the investment results of an index composed of a broad range of large-, mid-, and small-capitalisation emerging market equities.

“Prolia is a prescription medicine used to treat osteoporosis in women who have been through menopause and in men who are at increased risk of fractures, bone loss linked to hormone ablation in men with prostate cancer at increased risk of fractures and bone loss associated with long-term treatment with systemic glucocorticoids,” the company said in a regulatory filing dated November 24.

Furthermore, Xgeva is a prescription medicine used to prevent bone complications in adults with advanced cancer involving bone. It is also used for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone.

The EC decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) adopted in September 2025, it added.

The stock, which witnessed a one-way rally for the first few sessions from the IPO issue price of ₹100 to the record high of ₹193.80 on the NSE last week, has been volatile of late.

The company, on Friday, November 21, reported a 12% year-on-year (YoY) growth in its consolidated net profit to ₹471.33 crore in the September quarter (Q2 FY26), driven by an expanding user base and strong asset growth.

Headquartered in Bengaluru, the company had posted a net profit of ₹420.16 crore in the July-September quarter of the preceding fiscal year (FY25).

The company would develop this project in partnership with the landowner. The prices range from ₹2.8 crore to ₹5.75 crore.